Patents by Inventor Gerardo Enrique Guillén Nieto

Gerardo Enrique Guillén Nieto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210252109
    Abstract: The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.
    Type: Application
    Filed: August 19, 2019
    Publication date: August 19, 2021
    Inventors: Jorge Amador BERLANGA ACOSTA, Gerardo Enrique GUILLÉN NIETO, Diana GARCIA DEL BARCO HERRERA, Francisco HERNÁNDEZ BERNAL, Sonia GONZALEZ BLANCO, Raimundo UBIETA GÓMEZ
  • Publication number: 20210196793
    Abstract: The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the hexapeptide secretagogue GHRP6, useful for the restoration of brain damage, by stimulating mechanisms of differentiation and neuronal specialization in undifferentiated cells residing in the central nervous system or in neuronal cells. The invention also encompasses the use of the above mentioned biomolecules in the manufacture of a pharmaceutical combination for the restoration of brain damage. In addition, the invention provides a method of restoring brain damage in which a therapeutically effective amount of a pharmaceutical combination comprising EGF and GHRP6 is administered to a patient in need thereof. The efficacy of the pharmaceutical combination has a broad therapeutic window: it is independent of whether the pharmacological intervention occurs in the first or further hours after the brain damage, which broadens the therapeutic window.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 1, 2021
    Inventors: Diana GARCIA DEL BARCO HERRERA, Gerardo Enrique GUILLÉN NIETO, Mariela VAZQUEZ CASTILLO, Francisco HERNÁNDEZ BERNAL, Tatiana ZALDIVAR VAILLANT, Pablo Arsenio DIAZ REYES, ldania Caridad BALADRON CASTRILLO, Vladimir Armando BESADA PÉREZ, Sonia GONZALEZ BLANCO, Jorge Amador BERLANGA ACOSTA, Héctor Manuel PÉREZ SAAD
  • Publication number: 20210187101
    Abstract: The present invention relates to a rhinovaccination system for preventing and treating hepatitis B, comprising a hepatitis B vaccine composition for administration to nasal mucosa in combination with a medical nozzle device.
    Type: Application
    Filed: June 4, 2019
    Publication date: June 24, 2021
    Inventors: Taizou KAMISHITA, Takashi MIYAZAKI, Yoichi HIASA, Fazle Akbar SHEIKH MOHAMMAD, Osamu YOSHIDA, Julio Cesar AGUILAR RUBIDO, Gerardo Enrique GUILLEN NIETO, Eduardo PENTON ARIAS
  • Publication number: 20200297840
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 24, 2020
    Inventors: Julio César AGUILAR RUBIDO, Yadira LOBAINA MATO, Enrique IGLESIAS PEREZ, Eduardo PENTÓN ARIAS, Gerardo Enrique GUILLÉN NIETO, Jorge Agustín AGUIAR SANTIAGO, Sonia GONZALEZ BLANCO, Jorge VALDES HERNANDEZ, Mariela VAZQUEZ CASTILLO
  • Publication number: 20180256112
    Abstract: The present invention is related to a stereotaxic frame for extremities that ensures that the extremity position is fixed and reproducible; keeping the same geometric conditions of the measurement or treatment devices regards the extremity, or part thereof, during the study or therapy. The frame comprises a positioning and fixing holder for the extremity and a measuring or treatment system, that includes a geometric locus where the measurement or treatment device is allocated, ensuring that the relative position of said device regards the region of the extremity under examination or treatment is reproducible.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 13, 2018
    Inventors: Carlos Alberto CABAL MIRABAL, Evelio Rafael GONZÁLEZ DALMAU, Leonardo ORAMAS DIAZ, Luis Saturnino HERRERA MARTINEZ, Jorge Amador BERLANGA ACOSTA, José Ignacio FERNÁNDEZ MONTEQUÍN, Gerardo Enrique GUILLÉN NIETO, Luis Manuel FLORES DÍAZ, Orestes Lucio CABAÑAS RODRÍGUEZ, Sonia GONZALEZ BLANCO, Raimundo UBIETA GÓMEZ
  • Publication number: 20170119733
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Application
    Filed: November 10, 2016
    Publication date: May 4, 2017
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura
  • Patent number: 9518085
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 13, 2016
    Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECHNOLOGÍA
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura
  • Patent number: 9463235
    Abstract: Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: October 11, 2016
    Assignee: CENTRO DE INGENIERÍA GENEÉTICA Y BIOTECHNOLOGÍA
    Inventors: Lisset Hermida Cruz, Lázaro Gil González, Alienys Izquierdo Oliva, Ernesto Marcos López, Edith Suzarte Portal, Gerardo Enrique Guillén Nieto, María Guadalupe Guzmán Tirado, Iris Valdés Prado, Laura Lazo Vazquez, Angelica de la Caridad Garcia Arechavaleta, Mayling Alvarez Vera, Jorge Castro Velazco, Lázaro López Fernández, Rosa Liset Ramírez Bartutis, Yusleidi de la Caridad Pérez Fuentes, Olga Lidia Pérez Guevara, Yaremy Romero Fernández
  • Patent number: 9364524
    Abstract: A pharmaceutical composition using natural gonadotropin—releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 14, 2016
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Jesus Arturo Junco Barranco, Osvaldo Reyes Acosta, Eddy Emilio Bover Fuentes, Franklin Fuentes Aguilar, Eulogio Pimentel Vazquez, Roberto Basulto Baker, Gerardo Enrique Guillen Nieto, Yovisleidys Lopez Saez, Hilda Elisa Garay Perez, Lesvia Calzada Aguilera, Maria Castro Santana, Niurka Oneysi Arteaga More, Luis Alberto Aguero Barrocal
  • Publication number: 20150328304
    Abstract: Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 19, 2015
    Inventors: Lisset Hermida Cruz, Lázaro Gil González, Alienys Izquierdo Oliva, Ernesto Marcos López, Edith Suzarte Portal, Gerardo Enrique Guillén Nieto, María Guadalupe Guzmán Tirado, Iris Valdés Prado, Laura Lazo Vazquez, Angelica de la Caridad García Arechavaleta, Mayling Alvarez Vera, Jorge Castro Velazco, Lázaro López Fernández, Rosa Liset Ramírez Bartutis, Yusleidi de la Caridad Pérez Fuentes, Olga Lidia Pérez Guevara, Yaremy Romero Fernández
  • Publication number: 20150190491
    Abstract: A pharmaceutical composition using natural gonadotropin—releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers.
    Type: Application
    Filed: March 19, 2015
    Publication date: July 9, 2015
    Inventors: Jesus Arturo Junco Barranco, Osvaldo Reyes Acosta, Eddy Emilio Bover Fuentes, Franklin Fuentes Aguilar, Eulogio Pimentel Vazquez, Roberto Basulto Baker, Gerardo Enrique Guillen Nieto, Yovisleidys Lopez Saez, Hilda Elisa Garay Perez, Lesvia Calzada Aguilera, Maria Castro Santana, Niurka Oneysi Arteaga More, Luis Alberto Aguero Barrocal
  • Patent number: 9034826
    Abstract: The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as in ischemic neuritis.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: May 19, 2015
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Patent number: 8999931
    Abstract: A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: April 7, 2015
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jesus Arturo Junco Barranco, Osvaldo Reyes Acosta, Eddy Emilio Bover Fuentes, Franklin Fuentes Aguilar, Eulogio Pimentel Vazquez, Roberto Basulto Baker, Gerardo Enrique Guillen Nieto, Yovisleidys Lopez Saez, Hilda Elisa Garay Perez, Lesvia Calzada Aguilera, Maria Castro Santana, Niurka Oneysi Arteaga More, Luis Alberto Aguero Barrocal
  • Publication number: 20140356319
    Abstract: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.
    Type: Application
    Filed: June 29, 2012
    Publication date: December 4, 2014
    Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA
    Inventors: Giselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Pentón Arias, Efraín Rodríguez Jiménez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lázaro Pardo Andreu, Luis Javier González López, Nancy Pavón Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio López Saura
  • Patent number: 8722626
    Abstract: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: May 13, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jorge Berlanga Acosta, Danay Cibrian Vera, Diana Garcia Del Barco Herrera, Gerardo Enrique Guillén Nieto, José Suarez Alba, Ernesto Lopez Mola, Manuel Selman-Housein Sosa, Mariela Vazquez Castillo
  • Publication number: 20140105990
    Abstract: The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as in ischemic neuritis.
    Type: Application
    Filed: December 26, 2013
    Publication date: April 17, 2014
    Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Patent number: 8642552
    Abstract: The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: February 4, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Publication number: 20140011216
    Abstract: The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.
    Type: Application
    Filed: August 14, 2013
    Publication date: January 9, 2014
    Inventors: Diogenes Quintana Vazquez, Tamara Menendez Medina, Anabel Alvarez Acosta, Yoelys Cruz Leal, Gerardo Enrique Guillen Nieto
  • Patent number: 8569470
    Abstract: The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: October 29, 2013
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Diógenes Quintana Vázquez, Tamara Menendez Medina, Anabel Álvarez Acosta, Yoelys Cruz Leal, Gerardo Enrique Guillen Nieto
  • Patent number: 8431524
    Abstract: The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor ? (TNF?) induction and the expression of IL-8 and IL-6 by the IL-15 receptor ? subunit (IL-15R?), all these effects mediated by the binding of the peptide to the IL-15R?. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15R? is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: April 30, 2013
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Alicia Santos Savio, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Hilda Elisa Garay Perez, Yunier Rodriguez Alvarez, Gerardo Enríque Guillen Nieto